Trial of inosine pranobex in the management of cutaneous viral warts

Fifty patients with cutaneous mosaic warts resistant to standard therapy took part in a double-blind, placebo-controlled study to assess the efficacy of inosine pranobex used as an adjunct to standard topical treatments. No statistically significant difference was found in cure rates between the active (37.5%) and placebo treatments (34.6%) at 6 months, nor was there any relationship between clinical response and either antibody production or in vitro assay of lymphocyte proliferative activity against human papilloma virus (HPV) type 2 in either group.